Androgen Deprivation Therapy Market Size
| Study Period | 2018 - 2028 |
| Base Year For Estimation | 2021 |
| Forecast Data Period | 2024 - 2028 |
| CAGR | 5.20 % |
| Fastest Growing Market | North America |
| Largest Market | Asia-Pacific |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Androgen Deprivation Therapy Market Analysis
The Androgen Deprivation Therapy Market is expected to grow at a significant CAGR of 5.2% during the study period, 2022-2027.
The emergence of the COVID-19 pandemic had an adverse effect on the world economy and the healthcare system. It has impacted the androgen deprivation therapy market, as cancer patients, especially prostate cancer patients, are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by the malignancy and anticancer treatment. Thus, they were majorly suggested to stay at home and avoid all non-emergent treatment, which has impacted the market. Additionally, According to the study “Effects of Androgen Deprivation Therapy on COVID-19 in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis,” published in July 2021, ADT did not increase the mortality and morbidity of COVID-19 and should be considered a safe treatment for patients with prostate cancer during the pandemic. Such studies boosted the ongoing androgen therapy treatments. However, due to outages in the manufacturing plants, there was a supply chain disruption which has impacted the supply of the medication used for androgen deprivation therapy, thus, impacting the market.
The factors propelling the studied market growth are the rising burden of prostate cancer, increasing research and development activities, advancements in treatment technology for effective treatment of prostate cancer, rising product approvals, and strategic initiatives adopted by key market players.
As per the data published by GLOBOCAN, in 2020, the prevalence of prostate cancer was found to be 1,414,259, or 7.3% of the total cancer cases worldwide. The huge burden of prostate cancer globally generates the demand for effective treatment, hence driving the androgen deprivation therapy market.
According to an article published by the American Cancer Society in January 2022, prostate cancer is common among people aged 65 years and above. Therefore, the growing geriatric population will also boost the demand for its therapeutics, thus driving the market. According to World Population Prospects’ 2020 statistics, by 2050, 15 billion in the world will be over age 65 years, and at present, it is 727 million. Thus, the rising aging population in the world is expected to propel market growth.
Additionally, strategies such as partnerships, distribution agreements, mergers, and acquisitions adopted by key market players will boost the market growth. For instance, in May 2022, Myovant Sciences and Accord Healthcare, Ltd. entered into an exclusive license agreement for Accord to commercialize Relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (Relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland, and Turkey. Such partnerships will expand the accessibility of ORGOVYX across geographies, thereby leading to lucrative growth of the market.
Furthermore, the achievement of milestones in the drug development cycle will also fuel market growth. For instance, in May 2022, Bayer reported that the United States Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, limited reimbursement policies and increasing side effects is expected to hinder the market growth during the study period
Androgen Deprivation Therapy Market Trends
This section covers the major market trends shaping the Androgen Deprivation Therapy Market according to our research experts:
Antiandrogen Sub Segment Within Drug Class Segment is Expected to Account Large Market Share Over the Forecast Period
Anti-androgens are drugs that connect to the androgen receptors, inhibiting the androgens from causing tumor growth. Anti-androgens are also sometimes called androgen receptor antagonists. Antiandrogens drug include Flutamide (Eulexin), Bicalutamide (Casodex), Nilutamide (Nilandron), Enzalutamide (Xtandi), apalutamide (Erleada) and darolutamide (Nubeqa).
Factors such as rising incidences of prostate cancer globally, product approvals, growing geriatric population, increasing research and development activities, and strategies adopted by key market players such as partnerships will effectively contribute to the market growth.
The growing research activities in the segment are expected to fuel the market growth. For instance, In December 2021, Bayer published the results from the Phase III ARASENS trial, which investigated the use of the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide), an anti-androgen, in metastatic hormone-sensitive prostate cancer (mHSPC). The company stated that darolutamide, in combination with docetaxel and androgen deprivation therapy (ADT), significantly increased overall survival compared to docetaxel and ADT.
Additionally, in September 2021, Astellas Pharma Inc. and Pfizer Inc. stated that XTANDI (enzalutamide), an anti-androgen, improved overall survival in men with metastatic hormone-sensitive prostate cancer in which is proved through the ARCHES study. Such studies highlight the efficacies of anti-androgens in treating prostate cancer in terms of increased overall survival rate, which boosts the application of anti-androgen, hence driving the market.
Furthermore, In February 2021, Bayer, in partnership with Orion Corporation, expanded the global clinical development program for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in the area of prostate cancer. The company initiated a Phase III study ARANOTE which will evaluate the compound in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). Such strategies will allow companies to leverage others’ strengths and develop an advanced product in the area of prostate cancer, thereby leading to lucrative growth of the market.
Thus, due to the above-mentioned factors, the studied segment is expected to contribute to the significant growth of the market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The primary driving factors for the growth of the North American androgen deprivation therapy (ADT) market are the rising prevalence of prostate cancer, the growing geriatric population, product launches, and several initiatives and investments made by key market players.
The United States within North America is expected to hold a significant share of the studied market during the study period. Prostate cancer is the most common cancer in American men. The American Cancer Society estimates that in the United States, in 2022, about 268,490 new cases of prostate cancer and approximately 34,500 deaths from prostate cancer will be reported. Thus, a huge burden of prostate cancer n the country increases the demand for its therapeutics, which can suppress the amount of testosterone formed, thereby contributing to the market growth.
The above-mentioned source also suggests that prostate cancer is more likely to develop in older men. About 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age of men at diagnosis is about 66. Thereby, the growing elderly population in the region will also increase the incidence rate of prostate cancer, hence propelling the market.
The rising research and development studies that are proving the efficacies of androgen receptor inhibitors in treating pancreatic cancer will contribute to the market growth. For instance, in February 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson released results from the final analysis of the Phase 3 TITAN study stating that ERLEADA, in combination with ADT, provided a statistically significant improvement in overall survival rate with a 35% reduction in risk of death versus ADT alone. Such technological improvement in treatment procedures is expected to drive market growth.
In January 2021, the United States Food and Drug Administration approved Relugolix (Orgovyx) for treating adults with prostate cancer as it is more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment, leuprolide (Lupron).
Therefore, due to the above-mentioned factors, the studied market is expected to lead to lucrative growth of the market in North America.
Androgen Deprivation Therapy Industry Overview
The market is fragmented and moderately competitive. The strategies such as mergers and acquisitions and partnerships adopted by the key players will boost the market. The major players in the market are Johnson and Johnson, AstraZeneca, Bayer AG, Astellas Pharma, Tolmar Pharmaceuticals Inc., and others.
Androgen Deprivation Therapy Market Leaders
Johnson and Johnson
Astrazeneca
Bayer AG
Astellas Pharma Inc.
Tolmar Pharmaceuticals, Inc.
*Disclaimer: Major Players sorted in no particular order
Androgen Deprivation Therapy Market News
- In March 2022, Accord BioPharma, the United States specialty division of Intas Pharmaceuticals, Ltd. announced today the U.S. launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.
- In February 2022, BDR Pharmaceuticals launched its brand ENZALUTAMIDE, an antiandrogen in 160mg with brand name BDENZA for Prostate Cancer patients.
Androgen Deprivation Therapy Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Prostrate Cancer
4.2.2 Rising Research and Development Activities
4.3 Market Restraints
4.3.1 Poor Reimbursement and Increasing Side Effects
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
5.1 By Treatment
5.1.1 By Drug Class
5.1.1.1 Luteinizing Hormone-Releasing Hormone (LHRH) agonists
5.1.1.2 LHRH antagonists
5.1.1.3 Antiandrogens
5.1.2 By Surgery
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Oral
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Johnson and Johnson
6.1.2 Astrazeneca
6.1.3 Bayer AG
6.1.4 Astellas Pharma Inc.
6.1.5 AbbVie Inc.
6.1.6 Tolmar Pharmaceuticals, Inc.
6.1.7 Verity Pharmaceuticals Inc.
6.1.8 Foresee Pharmaceuticals Co., Ltd.
6.1.9 Myovant Sciences GmbH
6.1.10 Ferring B.V.
6.1.11 Viatris
6.1.12 Bristol-Myers Squibb Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Androgen Deprivation Therapy Industry Segmentation
As per the scope of the report, androgen deprivation therapy is hormone therapy for prostate cancer in males by suppressing the excess amount of androgen. Androgen is a sex hormone produced in the testes and adrenalin gland in the form of testosterone and dihydrotestosterone. The Androgen Deprivation Therapy Market is Segmented by Treatment ( Drug Class and Surgery), Route of Administration (Injectable and Oral), and Geography (North America, Europe, Asia Pacific, Middle-East, Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment | |||||
| |||||
| By Surgery |
| By Route of Administration | |
| Injectable | |
| Oral |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Androgen Deprivation Therapy Market Research FAQs
What is the current Global Androgen Deprivation Therapy Market size?
The Global Androgen Deprivation Therapy Market is projected to register a CAGR of 5.2% during the forecast period (2023-2028).
Who are the key players in Global Androgen Deprivation Therapy Market?
Johnson and Johnson, Astrazeneca, Bayer AG, Astellas Pharma Inc. and Tolmar Pharmaceuticals, Inc. are the major companies operating in the Global Androgen Deprivation Therapy Market.
Which is the fastest growing region in Global Androgen Deprivation Therapy Market?
North America is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Global Androgen Deprivation Therapy Market?
In 2023, the Asia-Pacific accounts for the largest market share in the Global Androgen Deprivation Therapy Market.
Global Androgen Deprivation Therapy Industry Report
Statistics for the 2023 Global Androgen Deprivation Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Androgen Deprivation Therapy analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
